An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (NCT07197866)

🧪 Interventions in This Study

• TEV-56286 (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Completion of the treatment period and the week 48(V9) visit of the double-blind trial (TV56286-NDG-20039) whilst remaining compliant with trial requirements
2. Females of childbearing potential may be included only if they have a negative pregnancy test at the baseline visit
3. Females of childbearing potential whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods for the duration of the trial and for 28 days after the last does of IMP
4. Males who are potentially fertile/reproductively competent (not surgically \[eg, vasectomy\] or congenitally sterile) and their female partners who are of childbearing potential must use, together with their female partners, highly effective birth control methods for the duration of the trial and for 28 days after the last dose of investigational medicinal product NOTE - Additional criteria apply, please contact the investigator for more information

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (32 Sites)

Showing the first 25 of 32 sites.

• Teva Investigational Site 15554 — La Jolla, California
• Teva Investigational Site 15544 — Boca Raton, Florida
• Teva Investigational Site 15555 — Tampa, Florida
• Teva Investigational Site 15549 — New York, New York
• Teva Investigational Site 15551 — New York, New York
• Teva Investigational Site 15548 — Pittsburgh, Pennsylvania
• Teva Investigational Site 15543 — Spokane, Washington
• Teva Investigational Site 35290 — Bordeaux,
• Teva Investigational Site 35291 — Paris,
• Teva Investigational Site 35292 — Toulouse,
• Teva Investigational Site 32818 — Dresden,
• Teva Investigational Site 32822 — Düsseldorf,
• Teva Investigational Site 32825 — Kassel,
• Teva Investigational Site 32824 — Marburg,
• Teva Investigational Site 32820 — München,
• Teva Investigational Site 32819 — Münster,
• Teva Investigational Site 80203 — Haifa,
• Teva Investigational Site 80204 — Tel Aviv,
• Teva Investigational Site 30299 — Bologna,
• Teva Investigational Site 30298 — Milan,
• Teva Investigational Site 30296 — Roma,
• Teva Investigational Site 30295 — Salerno,
• Teva Investigational Site 84137 — Niigata,
• Teva Investigational Site 84138 — Sagamihara,
• Teva Investigational Site 84141 — Sanda-shi,

📞 Contact the Study Coordinator

Phone: (888) 483-8279

Email: USMedInfo@tevapharm.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple System Atrophy

• Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy — Rochester, Minnesota
• A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy — Los Angeles, California
• A Study of Lu AF82422 in Participants With Multiple System Atrophy — Fountain Valley, California
• Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies — Lexington, Kentucky
• GDNF Gene Therapy for Multiple System Atrophy — Irvine, California

Explore by condition: All Multiple System Atrophy clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.